Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J C Cusack

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Surgical Oncology Clinics of North America|June 13, 1998
Cancer gene therapyJ C Cusack, K K Tanabe
Cancer Research|May 16, 2000
Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activationJ C Cusack, R Liu, A S Baldwin
Nature Medicine|April 15, 1999
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaBC Y Wang, J C Cusack, R Liu, et al.
Oncogene|March 9, 2010
Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cellsC M Sloss, F Wang, M A Palladino, et al.
American Journal of Surgery|October 1, 1994
Managing unsuspected tumor invasion of the superior mesenteric-portal venous confluence during pancreaticoduodenectomyJ C Cusack, G M Fuhrman, J E Lee, et al.
International Journal of Oncology|June 15, 2000
Fas and Fas ligand interactions in malignant diseaseL Owen-Schaub, H Chan, J C Cusack, et al.
Journal of the American College of Surgeons|September 18, 1997
Role of splenectomy in chronic lymphocytic leukemiaJ C Cusack, J F Seymour, S Lerner, et al.
Oncogene|September 27, 2006
Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistanceF Wang, R Liu, S W Lee, et al.
Cancer Gene Therapy|July 1, 1996
High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirusJ C Cusack, F R Spitz, D Nguyen, et al.
Cancer Research|April 28, 2001
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibitionJ C Cusack, R Liu, M Houston, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Surgical Oncology Clinics of North America|June 13, 1998
Cancer gene therapyJ C Cusack, K K Tanabe
Cancer Research|May 16, 2000
Inducible chemoresistance to 7-ethyl-10-[4-(1-piperidino)-1-piperidino]-carbonyloxycamptothe cin (CPT-11) in colorectal cancer cells and a xenograft model is overcome by inhibition of nuclear factor-kappaB activationJ C Cusack, R Liu, A S Baldwin
Nature Medicine|April 15, 1999
Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF-kappaBC Y Wang, J C Cusack, R Liu, et al.
Oncogene|March 9, 2010
Activation of EGFR by proteasome inhibition requires HB-EGF in pancreatic cancer cellsC M Sloss, F Wang, M A Palladino, et al.
American Journal of Surgery|October 1, 1994
Managing unsuspected tumor invasion of the superior mesenteric-portal venous confluence during pancreaticoduodenectomyJ C Cusack, G M Fuhrman, J E Lee, et al.
International Journal of Oncology|June 15, 2000
Fas and Fas ligand interactions in malignant diseaseL Owen-Schaub, H Chan, J C Cusack, et al.
Journal of the American College of Surgeons|September 18, 1997
Role of splenectomy in chronic lymphocytic leukemiaJ C Cusack, J F Seymour, S Lerner, et al.
Oncogene|September 27, 2006
Heparin-binding EGF-like growth factor is an early response gene to chemotherapy and contributes to chemotherapy resistanceF Wang, R Liu, S W Lee, et al.
Cancer Gene Therapy|July 1, 1996
High levels of gene transduction in human lung tumors following intralesional injection of recombinant adenovirusJ C Cusack, F R Spitz, D Nguyen, et al.
Cancer Research|April 28, 2001
Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor-kappaB inhibitionJ C Cusack, R Liu, M Houston, et al.
Pageof 3